Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An update from Vaxcyte (PCVX) is now available.
Vaxcyte, Inc. revealed promising initial results from its study on VAX-31, a vaccine candidate for preventing invasive pneumococcal disease in adults over 50. The Phase 1/2 trial showed that the vaccine was safe, well-tolerated, and effective in generating an immune response, indicating potential for future use in combating this serious infection.
Learn more about PCVX stock on TipRanks’ Stock Analysis page.
